Ziv-Aflibercept
Ziv-Aflibercept is a biological therapy with 29 clinical trials. Currently 2 active trials ongoing. Historical success rate of 87.0%.
Success Metrics
Based on 20 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
18
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
76.9%
20 of 26 finished
23.1%
6 ended early
2
trials recruiting
29
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Clinical Trials (29)
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 29